Education
About Us
Working with TipRanks
Follow Us
BrightSpring Health Services, Inc. (BTSG)
NASDAQ:BTSG
Earnings Data
Report Date
May 01, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.29Last Year’s EPS
0.19Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call was predominantly positive: BrightSpring reported strong 2025 results with robust revenue (28% YoY) and EBITDA (34% YoY) growth, meaningful improvement in cash flow and leverage, high-quality operational metrics across business lines, and confident 2026 guidance (midpoint implying ~14% revenue and ~25% EBITDA growth). Management also outlined strategic M&A activity (Amedisys acquisition) and a pending Community Living divestiture expected to generate ~$715M of net proceeds to further reduce leverage. Offsetting these positives are notable near-term headwinds from IRA and brand-to-generic conversions (gross impacts quantified in the hundreds of millions), disruption from a large customer bankruptcy and exit of uneconomic customers, and integration/timing risk related to acquired assets. Overall, the highlights—strong growth, cash generation, margin expansion, and balance sheet improvement—outweigh the lowlights, which are being actively managed.Company Guidance
Strong Top-Line and EBITDA Growth (2025)
Full year 2025 total revenue of $12.9B, representing 28% year-over-year growth; full year adjusted EBITDA of $618M, up 34% year over year. Fourth quarter revenue grew ~29% and adjusted EBITDA grew ~41% versus prior-year quarter.
Pharmacy Solutions Momentum
Pharmacy Solutions revenue of $11.4B for 2025 (31% YoY growth). Q4 pharmacy revenue grew 32% and adjusted EBITDA grew 44% YoY. Specialty & infusion revenue grew 43% in Q4; specialty and infusion script growth ~30% YoY in Q4. Total pharmacy script volume 10.8M in the quarter.
Provider Services Growth and Margin Expansion
Provider Services 2025 revenue $1.5B (11% YoY). Q4 provider revenue grew 13% YoY and segment adjusted EBITDA grew 16% with adjusted EBITDA margin of 16.4% (up ~50 basis points YoY). Home health revenue grew 19% and average daily census grew 15% to ~35,000 in Q4.
Cash Flow and Balance Sheet Improvement
Operating cash flow of $490M for 2025 (Q4 CFO $232M). Net debt $2.5B as of 12/31/2025. Leverage improved to 2.99x (down from 4.16x a year earlier) and management expects pro forma leverage of ~2.6x after Community Living divestiture; longer-term target of 2.5x or below.
Strategic M&A and Capital Deployment
Acquisition of 107 Amedisys branches for $239M (cash funded) generating pro forma revenue of $345M for 2025; expected contribution of ~$30M to 2026 adjusted EBITDA from Amedisys and LHC. Announced plan to divest Community Living with expected net after-tax proceeds of ~$715M to be used primarily for debt paydown.
Operational and Quality Achievements
Adjusted EBITDA margin expansion overall (4.8% for 2025, +20bps YoY). Strong quality and service metrics: home health >91% of branches 4+ stars and 99.4% timely initiation of care; hospice CAHPS overall rating 87% (top 5% program); dispensing accuracy 99.99%, order completeness 99.3%, on-time delivery 96.8%; infusion patient satisfaction 94%.
Ongoing Growth Drivers and Product Pipeline
LDD (limited distribution drug) portfolio at 149 LDDs with 24 launches in 2025 and 5 in Q4; company expects 16–20+ LDD launches over the next 12–18 months. Management cites continued drivers: new LDDs, generic utilization, fee-for-service growth, commercial execution and infusion expansion.
Forward Guidance for 2026
2026 guidance (continuing operations): total revenue $14.45B–$15.0B (implying ~11.9%–16.2% growth over 2025 excluding Community Living); total adjusted EBITDA $760M–$790M (23.1%–27.9% growth over 2025 excluding Community Living). Management expects ~14% revenue growth and ~25% adjusted EBITDA growth at the midpoints.
BrightSpring Health Services, Inc. (BTSG) Earnings, Revenues Date & History
BTSG Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BTSG Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 27, 2026 | $40.13 | $41.43 | +3.24% |
Oct 28, 2025 | $34.00 | $34.05 | +0.15% |
Aug 01, 2025 | $20.65 | $19.64 | -4.89% |
May 02, 2025 | $17.90 | $20.87 | +16.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BrightSpring Health Services, Inc. (BTSG) report earnings?
BrightSpring Health Services, Inc. (BTSG) is schdueled to report earning on May 01, 2026, Before Open (Confirmed).
What is BrightSpring Health Services, Inc. (BTSG) earnings time?
BrightSpring Health Services, Inc. (BTSG) earnings time is at May 01, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BTSG EPS forecast?
BTSG EPS forecast for the fiscal quarter 2026 (Q1) is 0.29.